Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
2023年12月30日 - 1:26AM
Edgar (US Regulatory)
|
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
|
|
|
|
|
|
FORM 12b-25 |
SEC FILE NUMBER
000-52218 |
|
NOTIFICATION OF LATE FILING |
CUSIP NUMBER
68235A200 |
(Check
one): |
☒ |
Form
10-K |
☐ |
Form
20-F |
☐ |
Form
11-K |
☐ |
Form
10-Q |
☐ |
Form
10-D |
☐ |
Form
N-CEN |
☐ |
Form
N-CSR |
|
For Period Ended: |
September 30, 2023 |
|
|
|
|
|
☐ |
Transition Report on Form 10-K |
|
|
|
|
|
☐ |
Transition Report on Form 20-F |
|
|
|
|
|
☐ |
Transition Report on Form 11-K |
|
|
|
|
|
☐ |
Transition Report on Form 10-Q |
|
For
the Transition Period Ended: |
|
Read
Instructions (on back page) Before Preparing Form. Please Print or Type. |
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein. |
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: |
|
|
PART
I — REGISTRANT INFORMATION |
Theralink
Technologies, Inc. |
Full
Name of Registrant |
|
|
Former
Name if Applicable |
|
15000
W. 6th Ave., #400 |
Address
of Principal Executive Office (Street and Number) |
|
Golden,
CO 80401 |
City,
State and Zip Code |
PART
II — RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if appropriate)
|
(a) |
The
reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
|
|
|
☒ |
(b) |
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or
portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly
report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or
before the fifth calendar day following the prescribed due date; and |
|
|
|
|
(c) |
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART
III — NARRATIVE
State
below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion
thereof, could not be filed within the prescribed time period. (Attach extra Sheets if Needed)
Theralink Technologies, Inc., a Nevada corporation (the “Company”), is filing this Notification of Late Filing on Form 12b-25 with respect to its Annual Report on Form 10-K for the year ended September 30, 2023 (the “Form 10-K”).
The Company could not complete the filing of its Annual Report on Form 10-K for the period ended September 30, 2023, due to a delay in obtaining and compiling information required to be included in the Company’s Form 10-K, which delay could not be eliminated by the Company without unreasonable effort and expense. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, as amended, the Company will file its Form 10-K no later than the fifteenth calendar day following the prescribed due date.
PART
IV — OTHER INFORMATION
(1) |
Name
and telephone number of person to contact in regard to this notification |
|
Andrew
Kucharchuk |
|
(888) |
|
585-4923 |
|
(Name) |
|
(Area
Code) |
|
(Telephone
Number) |
(2) |
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If answer is no, identify report(s). |
|
Yes
☒ No ☐ |
|
|
(3) |
Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or portion thereof? |
|
Yes
☐ No ☒ |
|
|
|
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made. |
Theralink
Technologies, Inc.
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date: |
December 29, 2023 |
|
By: |
/s/
Andrew Kucharchuk |
|
|
|
|
Andrew
Kucharchuk |
|
|
|
|
Chief
Financial Officer |
Theralink Technologies (CE) (USOTC:THER)
過去 株価チャート
から 11 2024 まで 12 2024
Theralink Technologies (CE) (USOTC:THER)
過去 株価チャート
から 12 2023 まで 12 2024
Real-Time news about Theralink Technologies Inc (CE) (その他OTC): 0 recent articles
その他のTheralink Technologies Inc (PK)ニュース記事